We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Draft Guidance on Coverage with Evidence Development Released by CMS

Stuart M. Langbein

Stuart M. Langbein,

Washington, D.C.

Beth Halpern

Emily Gebbia

04 December 2012
On November 29, 2012, the Centers for Medicare & Medicaid Services (CMS) released Draft Guidance on Coverage with Evidence Development (CED).  CMS first issued guidance on the use of CED in making coverage determinations in 2006.  The Draft Guidance is intended to make revisions to that document “in light of lessons learned” and based on public comments and on public testimony and panel recommendations made at a Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting earlier in the year.  The goal is to increase the use of CED in coverage determinations. 
Draft Guidance on Coverage with Evidence Development Released by CMS

A few of the more noteworthy provisions in the Draft CED Guidance include the following:

  • CMS is proposing to no longer use the coverage with appropriateness determination (CAD) but instead, to reflect the fact that recent CED national coverage determinations (NCDs) have “all been designed around research questions.” CMS will use CED only in connection with the conduct of research (i.e., pursuant to its authority under section 1862(a)(1)(E) of the Social Security Act).
  • CMS indicates that it will consider applying CED not only to new technologies for which there is an insufficient evidence base, but also for existing technologies where “new research or evolving scientific thought raises important questions about the clinical usefulness, and thus the medical necessity,” of such technologies.
  • CMS provides specific guidance on how CED studies should be designed, including that the principal purpose is to test whether the item or service “meaningfully improves health outcomes of patients who are represented by the enrolled subjects”; the study protocol specifies the method and timing of public release of results on all pre-specified outcomes; and the study protocol explicitly discusses subpopulations affected by the item or service under investigation, particularly traditionally underrepresented groups in clinical studies.
  • CMS indicates that CED ends when the CED studies are completed and explicitly states that, under CED, “there is a potential period of noncoverage between the end of the study and the agency’s review of the scientific results.”  However, the agency indicates a willingness to attempt to avoid such coverage gaps.
  • CMS declined to establish formalized evidentiary criteria for CED as urged by commenters and recommended by MEDCAC.
  • CMS states that is expects that results of all CED approved studies will be analyzed and published in peer reviewed clinical journals.

CMS will accept public comment on the Draft CED Guidance until January 28, 2013.

Stuart M. Langbein

Stuart M. Langbein,

Washington, D.C.

Beth Halpern

Emily Gebbia

Loading data